Since 2018, Sean has served the financial community as Chief Options Strategist for All Star Charts, sharing his unique style of options trading, leveraging the best-in-class technical analysis offered by the All Star Charts research team.
In all endeavors, Sean has been consistent in building a support system around himself and for others that he wishes he had when he started out back in 1998.
When my friend and client—who manages a three-commas portfolio—calls me with a trade idea, I listen.
Sure, he’s human like the rest of us. Prone to bias, emotion, and the occasional bad read. But over the years, he’s earned my respect. He’s sharp, curious, and often brings fresh perspective to the table. So when his name pops up on my phone, I answer.
This week, he rang me up to talk about a stock that’s down 95% from its highs.
I’ll be honest—where I come from, we call that dumpster diving.
But as he laid out his case, I started to lean in.
He noted signs of a likely turn in the broader sector. He pointed out a major price gap from ten months ago that, if filled, could offer serious upside. And he reminded me that the stock in question is a “story stock”—the kind momentum traders love to chase if the price action gives them the green light.
While we talked, I pulled up the options chain and started scanning out in time—way out.
I found a June 2026 call with a roughly 1-in-4 shot of landing in the money. But if we’re right and that gap fills? That option could return 30x.
Today's trade is in a stock that has been seemingly left for dead. Which is ironic, considering this company is engaged in keeping people alive.
This biotech company is an astounding 95% off it's 2021 highs.
But here's the thing... this stock just crossed above its 50-day moving average and appears to be holding there. And with a new leg higher in the stock market likely to lift a lot of boats, there is opportunity here.